{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:59:03Z","timestamp":1761580743791},"reference-count":25,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1253\/circj.cj-09-0367","type":"journal-article","created":{"date-parts":[[2009,12,25]],"date-time":"2009-12-25T06:01:47Z","timestamp":1261720907000},"page":"71-76","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Antiarrhythmics Used in Patients With Paroxysmal Atrial Fibrillation:"],"prefix":"10.1253","volume":"74","author":[{"given":"Yoshiyasu","family":"Aizawa","sequence":"first","affiliation":[{"name":"Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Atarashi","sequence":"additional","affiliation":[{"name":"Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Kamakura","sequence":"additional","affiliation":[{"name":"National Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Hokko Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruaki","family":"Nakaya","sequence":"additional","affiliation":[{"name":"Chiba University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Fukatani","sequence":"additional","affiliation":[{"name":"Chikamori Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Mitamura","sequence":"additional","affiliation":[{"name":"Saiseikai Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"J-RHYTHM Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.","DOI":"10.1161\/01.CIR.98.10.946"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113: 365-370.","DOI":"10.1016\/S0002-9343(02)01253-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.","DOI":"10.1016\/S0002-9343(99)80348-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: A prospective cohort of Shinken Database 2004. Circ J 2008; 72: 914-920.","DOI":"10.1253\/circj.72.914"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hohnloser SH, Kuck KH, Liliethal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet 2000; 356: 1789-1794.","DOI":"10.1016\/S0140-6736(00)03230-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.","DOI":"10.1056\/NEJMoa021328"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.","DOI":"10.1056\/NEJMoa021375"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.","DOI":"10.1016\/S0735-1097(03)00332-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109: 1973-1980.","DOI":"10.1161\/01.CIR.0000118472.77237.FA"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-248.","DOI":"10.1253\/circj.CJ-08-0608"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. The Japanese Guidelines for Atrial Fibrillation Management. Jpn Circ J 2001; 65(Suppl V): 931-979 (in Japanese).","DOI":"10.1253\/jcj.65.931"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, et al. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 2003; 67: 738-741.","DOI":"10.1253\/circj.67.738"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.","DOI":"10.1093\/eurheartj\/ehm315"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management: The AFFIRM study design. Am J Cardiol 1997; 79: 1198-1202.","DOI":"10.1016\/S0002-9149(97)00082-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, et al. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-666.","DOI":"10.1253\/circj.70.662"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, et al. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ J 2006; 70: 1138-1141.","DOI":"10.1253\/circj.70.1138"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishida K, Fujiki A, Sakamoto T, Iwamoto J, Mizumaki K, Hashimoto N, et al. Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial tachycardia. J Cardiovasc Electrophysiol 2007; 18: 765-772.","DOI":"10.1111\/j.1540-8167.2007.00833.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257.","DOI":"10.1253\/circj.71.1250"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, et al. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms. Circ J 2009; 73: 1020-1027.","DOI":"10.1253\/circj.CJ-08-1061"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257.","DOI":"10.1253\/circj.71.1250"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.","DOI":"10.1056\/NEJMoa041705"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920.","DOI":"10.1056\/NEJM200003303421302"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H; Sinus Rhythm Maintenance in Atrial Fibrillation Randomized Trial (SMART) Investigators. Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. Circ J 2002; 66: 553-556.","DOI":"10.1253\/circj.66.553"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ogawa S. Selection of anti-arrhythmia agents: Application of the Sicilian Gambit. Nippon Naika Gakkai Zasshi 1999; 88: 432-435.","DOI":"10.2169\/naika.88.432"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/74\/1\/74_CJ-09-0367\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T19:49:23Z","timestamp":1558727363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/74\/1\/74_CJ-09-0367\/_article"}},"subtitle":["Subanalysis of J-RHYTHM Study"],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-09-0367","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}